Notes from JB Chemicals AR for FY 21-22 –
- JBC was the fastest growing Pharma company among top 30 companies in the Indian Pharma market in FY 21-22. Company has 07 manufacturing facilities in India. 05 of its power brands feature in India’s top 300 brands. These are –
Rantac ( to treat heartburn, indigestion ), Rank- 45
Cilacar ( to treat high BP ), Rank- 52
Cilacar-T ( to treat high BP ), Rank – 203
Metrogyl ( to treat bacterial infections ), Rank- 194
Nicardia ( to treat high BP ), Rank – 240
- Key growth initiatives during the year –
(a) New go to market model focusing on increasing MR productivity and renewed focus on domestic business
(b) Increased focus on chronic segments. Acquired Azmarda ( Scaubitril + Valsartan ) from Novartis – used to treat heart failure, a fast growing category.
(c) Launched 15 products in domestic market. Contribution from new launches stands at 4pc, up from 1.4 pc last yr.
(d) Acquired 06 brands from Sanzyme. These are –
Sporlac ( probiotic used to treat gas and diarrhoea )
Lobun ( prebiotic used to treat chronic kidney disease)
Oxalo ( probiotic to treat constipation, diarrhoea )
Nano-Leo ( capsules to improve male sexual health )
Pubergen ( Injectable hormone to support pregnancy )
Gynogen ( Injection to treat infertility )
(e) Beyond India, SA and Russia are company’s strong markets. JBC was the fastest growing company in SA last yr. Company is ranked 15 in SA. Russian demand remains stable despite geo-political headwinds.
(f) In US, company to focus on low volume, high value products with own APIs as backward integration.
(g) Company’s CMO business, specially Lozenges represents an area of excellence with company being among top 5 companies globally. Aims to maintain the same. Also aims to focus on immunity based products here, beyond cold and cough products to improve growth rates.
- Last 5 yr data –
Sales – 1413, 1643, 1775, 2043, 2424 cr
EBITDA – 217, 305,378, 560,543 cr
EBITDA margins – 15pc, 19pc, 21pc, 27pc, 22pc
Disc: invested, biased
| Subscribe To Our Free Newsletter |
